Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810... read more
Harpoon Therapeutics announced that it will raise up to $93 million in its IPO. The company is offering 5,400,000 shares and is granting underwriters the option to purchase up to an additional 810... read more
Avedro, Inc. (“Avedro”), a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or... read more
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company developing the next generation of novel T cell receptor therapies for patients suffering from cancer, today announced that it has... read more
Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) announcedon 2/1/19 the expiration of the waiting period under the Hart-Scott-Rodino Antitrust... read more